Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance

NCT01141504 | Completed Phase 1

• 1 other identifier: MTI2010-CS01
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

Adenosine-triphosphate (ATP) serves as the sole energy source for muscle contraction. Therefore human performance of brief maximal exercise is limited, in part, by the availability of ATP to the contracting muscle. Because muscle ATP storage is small (enough to sustain maximal exercise for less than 1 second), factors that enhance either storage or resynthesis of ATP may have a positive impact on repeated muscle contractions. The current study will test the hypothesis that increasing ATP availability to muscle via oral supplementation will improve performance of repeated high intensity exercise as measured by a) work performed in each of the three 50 contraction fatigue tests, b) sum of total work performed, and c) percentage decrement in total work from the first to third third 50 contraction test.

Conditions

Healthy Subjects

Keywords

Supplemental ATP; Muscle Work Performed; Muscle Fatigue

Outcome Measures

Primary Outcomes (1)

• Work Performed

  The work and total work performed in 3 exercise fatigue tests given after 15 days of nutritional intervention.

  Measured after 15 days of intervention

Secondary Outcomes (1)

• Decrease in work performed in each successive test

  Measured after 15 days of intervention

Study Arms (4)

Placebo

PLACEBO COMPARATOR

Oral placebo capsules similar in color and size to the intervention

Dietary Supplement: Placebo

PeakATP 250

ACTIVE COMPARATOR

Oral supplement capsules containing 250 mg/day of PeakATP

Dietary Supplement: PeakATP 250

PeakATP 400

ACTIVE COMPARATOR

Oral supplement capsules containing 400 mg/day of PeakATP

Dietary Supplement: PeakATP 400

PeakATP 400 plus proprietary blend

ACTIVE COMPARATOR

Oral supplement capsules containing 400 mg/day of PeakATP plus a proprietary blend

Dietary Supplement: PeakATP 400 plus proprietary blend

Interventions

PeakATP 250 DIETARY_SUPPLEMENT

The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day

PeakATP 250

Placebo DIETARY_SUPPLEMENT

Placebo capsules that are comparable in size and color to the active comparator for blinding purposes

Placebo

PeakATP 400 DIETARY_SUPPLEMENT

The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day

PeakATP 400

PeakATP 400 plus proprietary blend DIETARY_SUPPLEMENT

The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients

PeakATP 400 plus proprietary blend

Eligibility Criteria

• Age: 20 Years - 30 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• No major medical conditions;
• Able to perform fatigue testing procedures;
• Not currently taking prescription medications;
• Not currently taking dietary supplements (a daily multi-vitamin not exceeding RDA is permitted)

You may not qualify if:

• Major medical condition affecting metabolism or general function;
• Not able to perform fatigue testing;
• Taking prescription medications;
• Taking a dietary supplement other than a multi-vitamin not exceeding RDA

Sponsors & Collaborators

• Metabolic Technologies Inc.: lead
• Iowa State University: collaborator

Study Sites (1)

Iowa State University

Ames, Iowa, 50010, United States

Location

Study Officials

• John A Rathmacher, PhD

  Metabolic Technologies Inc.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 9, 2010
• First Posted: June 10, 2010
• Study Start: June 1, 2010
• Primary Completion: October 1, 2011
• Study Completion: October 1, 2011
• Last Updated: January 10, 2012

Record last verified: 2012-01

Locations

US (1)